ALA Diagnostics Opens a New Laboratory in Madrid After Joining BeAble Capital

ALA Diagnostics expands its business in the capital of Spain. The Spanish biotechnology company specializing in the development of in vitro diagnostic kits for pathologies with high prevalence or unmet medical needs has launched a new laboratory at number 27 López de Hoyos Street in Madrid, as explained by José Ramón Montero, founding partner and general director of ALA Diagnostics.

The objective of these facilities is to provide the company with the necessary infrastructure to be able to concentrate the production activities of the components of its diagnostic kit, complete clinical trials, and centralize the management of the company.

To do this, the company has installed two laboratories, one general for research and development (R&D) and another for crops, and a cold room. The spaces have all the necessary equipment for the activities planned until the commercialization of its first ALA Diagnostics EM Kit product, as well as offices and a meeting room, where all activities are centralized.

Read more about ALA Diagnostics and find the most important financial news of the day with the Born2Invest mobile app.

ALA Diagnostics closed a financing round of €1.1 million in June

In the general laboratory, R&D activities are carried out, including Elisas, which is a laboratory test commonly used to detect antibodies in the blood, in addition to the production of protein batches and preparation of the media necessary for the diagnostic kit.

In the culture laboratory, the company works on the production of monoclonal antibodies. “To do this, it is necessary to have equipment that allows working in controlled CO2 conditions and maintaining sterile conditions,” explains Montero.

This new commitment by the company occured after last June the company closed a financing round of €1.1 million led by BeAble Capital, which took a minority stake in the company.

At the beginning of the year, ALA Diagnostics received a subsidy of more than half a million euros from the European Commission

The company will complete the development of its diagnostic kit and will undertake international clinical trials in the coming months that will allow the product to be marketed in Europe and the United States.

ALA Diagnostics was born in 2019,  as a result of the identification of an opportunity for the development of a blood diagnostic kit for Multiple Sclerosis, applicable to the early diagnosis of the disease, based on a recombinant protein whose activity as a diagnostic biomarker has already been validated. in clinical studies.

In 2021, the company closed its first round of financing for the development of the ALA Diagnostics Em Kit, the first test for the early diagnosis of Multiple Sclerosis in blood. The test is based on a recombinant protein whose activity as a diagnostic biomarker has already been validated in more than 500 human samples. In addition, at the beginning of the year, the company received a non-refundable subsidy of more than half a million euros from the European Commission for research and development (R&D) activities.

José Ramón Montero, in addition to being the general director of the company, has fourteen years of experience in the biotechnology sector, performing functions related to the management of research, development, and innovation (R&D&I) projects, feasibility analysis of projects, preparation of business plans, business strategy and advising biotechnology startups. He is accompanied on the management team by Óscar Fernández, a clinical neurologist with more than forty years of experience. The founding team retains the majority of the company’s capital.

__

(Featured image by c1n3ma via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.